Celyad Oncology SA
Celyad Oncology SA, a biotechnology company, focuses on the research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through Immuno-Oncology and Cardiology segments. The company develops short hairpin ribonucleic acid (shRNA) non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding … Read more
Celyad Oncology SA (CLYYF) - Total Assets
Latest total assets as of June 2025: $5.70 Million USD
Based on the latest financial reports, Celyad Oncology SA (CLYYF) holds total assets worth $5.70 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Celyad Oncology SA - Total Assets Trend (2010–2024)
This chart illustrates how Celyad Oncology SA’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Celyad Oncology SA - Asset Composition Analysis
Current Asset Composition (December 2024)
Celyad Oncology SA's total assets of $5.70 Million consist of 65.6% current assets and 34.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 42.3% |
| Accounts Receivable | $908.00K | 9.2% |
| Inventory | $417.00K | 4.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $405.00K | 4.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2010–2024)
This chart illustrates how Celyad Oncology SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Celyad Oncology SA's current assets represent 65.6% of total assets in 2024, an increase from 37.0% in 2010.
- Cash Position: Cash and equivalents constituted 42.3% of total assets in 2024, up from 21.9% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 58.0% in 2010.
- Asset Diversification: The largest asset category is accounts receivable at 9.2% of total assets.
Celyad Oncology SA Competitors by Total Assets
Key competitors of Celyad Oncology SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Celyad Oncology SA - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Celyad Oncology SA generates 0.02x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Celyad Oncology SA is currently not profitable relative to its asset base.
Celyad Oncology SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.66 | 3.59 | 2.73 |
| Quick Ratio | 0.59 | 3.04 | 2.88 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.26 Million | $ 6.25 Million | $ 18.64 Million |
Celyad Oncology SA - Advanced Valuation Insights
This section examines the relationship between Celyad Oncology SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 15.45 |
| Latest Market Cap to Assets Ratio | 0.68 |
| Asset Growth Rate (YoY) | -39.0% |
| Total Assets | $9.93 Million |
| Market Capitalization | $6.71 Million USD |
Valuation Analysis
Below Book Valuation: The market values Celyad Oncology SA's assets below their book value (0.68 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Celyad Oncology SA's assets decreased by 39.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Celyad Oncology SA (2010–2024)
The table below shows the annual total assets of Celyad Oncology SA from 2010 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $9.93 Million | -39.02% |
| 2023-12-31 | $16.28 Million | -17.42% |
| 2022-12-31 | $19.72 Million | -75.34% |
| 2021-12-31 | $79.94 Million | +20.97% |
| 2020-12-31 | $66.08 Million | -26.44% |
| 2019-12-31 | $89.84 Million | -4.73% |
| 2018-12-31 | $94.30 Million | +21.48% |
| 2017-12-31 | $77.63 Million | -44.08% |
| 2016-12-31 | $138.81 Million | -12.99% |
| 2015-12-31 | $159.53 Million | +262.75% |
| 2014-12-31 | $43.98 Million | +35.79% |
| 2013-12-31 | $32.39 Million | +135.60% |
| 2012-12-31 | $13.75 Million | +99.87% |
| 2011-12-31 | $6.88 Million | -60.69% |
| 2010-12-31 | $17.50 Million | -- |